X
All Data
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): Oxypurinol
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Xortx Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 30, 2020
Details:
Lonza Pharma will be resposible for manufacturing of active pharmaceutical ingredient for XRx-101 and XRx-008 in response to support the drug development and clinical trial process for COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pamapimod,Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: KIN001
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2021
Details:
KIN001, a combination of p38 MAPK inhibitor pamapimod with a second drug has a proven safety record with potential to address a broad range of indications.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Alisporivir
Therapeutic Area: Infections and Infectious Diseases Product Name: Debio 025
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2021
Details:
Pre-clinical in vitro research from the Mondor Institute of Biomedical Research (INSERM U955) has shown evidence for the effectiveness of alisporivir against the replication of SARS-COV-2 (COVID-19).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MTX-COVAB
Therapeutic Area: Infections and Infectious Diseases Product Name: MTX-COVAB
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Swisscanto
Deal Size: $15.3 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 06, 2020
Details:
The proceeds of the financing will be used primarily to advance development of MTX-COVAB, Memo Therapeutic AG’s lead antibody candidate for the treatment of COVID-19 through to Phase II clinical studies, including production of GMP material.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aviptadil Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2020
Details:
The trial will enroll patients who are already on mechanical ventilati
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
